GeneSort

GeneSortGeneSort
GeneSort

GeneSort

A molecular diagnostics company focused on integrating genomics with personalized therapeutic approaches for cancer.

DR 2.52014Inactive4Tel Aviv, Israel
Rate

About

GeneSort was a molecular diagnostics company that focused on integrating molecular genomics with personalized therapeutic approaches. Its core technology leveraged patients' genetic DNA profiles to assist physicians in selecting tailored treatments, primarily for cancer and hereditary diseases. The company aimed to provide diagnostic services that helped oncologists adapt treatments to specific genetic mutations.
Frequently asked

What does GeneSort do?

GeneSort was a molecular diagnostics company that focused on integrating molecular genomics with personalized therapeutic approaches. Its core technology leveraged patients' genetic DNA profiles to assist physicians in selecting tailored treatments, primarily for cancer and hereditary diseases. The company aimed to provide diagnostic services that helped oncologists adapt treatments to specific genetic mutations.

What is GeneSort's revenue?

StartupHub estimates GeneSort's annual revenue at $731K (range $416K to $1.7M, 67% confidence), based on comparable companies in the sector.

What is GeneSort's valuation?

StartupHub estimates GeneSort's effective valuation at $8.3M (range $5.5M to $13.2M, 24% confidence), based on comparable companies in the sector.

How much funding has GeneSort raised?

GeneSort has raised a total of $2M in funding.

Where is GeneSort headquartered?

GeneSort is headquartered in Tel Aviv, Israel.

When was GeneSort founded?

GeneSort was founded in 2014.

What industry does GeneSort operate in?

GeneSort operates in Healthcare, Next Generation Sequencing, Cancer, Genomics, Molecular Diagnostics, HealthTech.

How many employees does GeneSort have?

GeneSort has approximately 4 people on record.

What is GeneSort's current status?

GeneSort's current operating status is: Inactive.

HEADCOUNT
4
DOMAIN RATING
2.5
Comments

No comments yet. Be the first to share your take.